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BACKGROUND: Testicular germ cell tumour (TGCT) patients are at increased risk of developing a contralateral testicular germ cell
tumour (CTGCT). It is unclear whether TGCT treatment affects CTGCT risk.
METHODS: The risk of developing a metachronous CTGCT (a CTGCT diagnosed X6 months after a primary TGCT) and its impact
on patient’s prognosis was assessed in a nationwide cohort comprising 3749 TGCT patients treated in the Netherlands during
1965–1995. Standardised incidence ratios (SIRs), comparing CTGCT incidence with TGCT incidence in the general population, and
cumulative CTGCT incidence were estimated and CTGCT risk factors assessed, accounting for competing risks.
RESULTS: Median follow-up was 18.5 years. Seventy-seven metachronous CTGCTs were diagnosed. The SIR for metachronous
CTGCTs was 17.6 (95% confidence interval (95% CI) 13.9–22.0). Standardised incidence ratios remained elevated for up to 20 years,
while the 20-year cumulative incidence was 2.2% (95% CI 1.8–2.8%). Platinum-based chemotherapy was associated with a lower
CTGCT risk among non-seminoma patients (hazard ratio 0.37, 95% CI 0.18–0.72). The CTGCT patients had a 2.3-fold (95% CI 1.3–4.1)
increased risk to develop a subsequent non-TGCT cancer and, consequently, a 1.8-fold (95% CI 1.1–2.9) higher risk of death than
patients without a CTGCT.
CONCLUSION: The TGCT patients remain at increased risk of a CTGCT for up to 20 years. Treatment with platinum-based
chemotherapy reduces this risk.
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Although most testicular germ cell tumour (TGCT) patients
present with a single affected testicle, in 0.5–1% bilateral TGCT
is diagnosed (Wandera˚s et al, 1997; Theodore et al, 2004; Fossa˚
et al, 2005; Hentrich et al, 2005). Testicular germ cell tumour
patients remain at increased risk of developing a contralateral
testicular germ cell tumour (CTGCT) during follow-up (Osterlind
et al, 1991; van Leeuwen et al, 1993; Wandera˚s et al, 1997; Fossa˚
et al, 2005; Andreassen et al, 2011). It remains unclear whether
primary treatment, especially platinum-based chemotherapy,
affects the risk of developing a metachronous CTGCT. In a
previous report from our institute we found a strongly increased
CTGCT risk compared with the general population after surgery or
radiotherapy but not after chemotherapy (van Leeuwen et al,
1993). Several other studies reported a higher CTGCT risk for
seminoma compared with non-seminoma TGCT patients, which
may reflect differences in treatment (Che et al, 2002; Theodore
et al, 2004; Fossa˚ et al, 2005). However, few studies directly
evaluated the effect of TGCT treatment on CTGCT risk, with
controversial results (van Basten et al, 1997; Wandera˚s et al, 1997).
This study assesses long-term CTGCT risk, risk factors for
developing a CTGCT and the impact of a CTGCT and its treatment
on patient prognosis in a large nationwide cohort of TGCT patients
treated in the Netherlands between 1965 and 1995.
PATIENTS AND METHODS
Patient selection and data collection have been described in detail
in earlier reports (van Leeuwen et al, 1993; van den Belt-Dusebout
et al, 2007). Briefly, TGCT patients were identified through the
former Netherlands Committee on Testicular Tumors registry
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(Zwaveling and Soebhag, 1985) and tumour registries at several
referral hospitals (Netherlands Cancer Institute, Daniel den Hoed
Cancer Center, University Medical Center Groningen and Amsterdam
Medical Center). For this study, an additional 357 patients treated
at the Radboud University Medical Center in 1982–1995 were also
included.
Data were collected on dates of birth and tumour diagnoses,
histology, primary and relapse treatment (radiation fields and
chemotherapy regimens), date and cause of death. Medical follow-
up regarding TGCT treatment and second malignancies (SMNs)
was obtained actively from medical charts, general practitioners
and attending physicians, and was complete until at least 1 January
2000, the date of death, or the date of emigration for 90% of all
patients (van den Belt-Dusebout et al, 2007). Subsequently, we
retrieved data on SMNs, including CTGCTs, diagnosed in the
period 1989–2007 from the Netherlands Cancer Registry and dates
of death or emigration up to January 2008 from the Dutch Central
Bureau for Genealogy and the Dutch municipal administrations.
Treatment
Changes in TGCT treatment after orchiectomy were described in
detail previously (van Leeuwen et al, 1993; van den Belt-Dusebout
et al, 2007). Briefly, stage I and II seminoma and non-seminoma
patients received radiotherapy to the para-aortic and ipsilateral
iliacal nodes (30–35 and 40–50 Gy in fractions of 2 Gy, respec-
tively). Since the mid-1980s, radiotherapy dose has been reduced
to 26 Gy for seminoma while surveillance became common for
stage I non-seminomas. Until the late 1970s treatment for
disseminated non-seminomas generally consisted of dactinomycin
alone or combined with vincristine, vinblastine or bleomycin. Both
disseminated seminomas and non-seminomas were treated
primarily with cisplatin, vinblastine and bleomycin (PVB) since
1977 and with bleomycin, etoposide and cisplatin (BEP) from the
mid-1980s. Besides PVB and BEP several other regimens have been
used, mainly within randomised trials. For this study all
chemotherapy regimens with cis- or carboplatin were categorised
as ‘Platinum-based’ while all other regimens were grouped under
‘Other’.
Statistical analysis
As most relapses occurred early, relapse treatment before a CTGCT
was combined with primary treatment. We compared CTGCT
incidence with age- and calendar year-specific TGCT incidence rates
for the Dutch population, accounting for person-years of observa-
tion. Cancer incidence data from the Eindhoven Cancer Registry for
1970–1988 and from the NCR for 1989–2009 were used as reference
rates (The Netherlands Cancer Registry: Cancer in figures, 2012).
Standardised incidence ratios (SIR) were calculated as observed
over expected number of CTGCTs and absolute excess risks (AER)
as the observed minus the expected CTGCT number, divided by
person-years at risk, times 10 000. Only metachronous CTGCTs,
defined as any CTGCT diagnosed X6 months after the primary
TGCT, were analysed. Time at risk therefore started 6 months after
TGCT diagnosis and ended at date of CTGCT diagnosis,
emigration, death or most recent medical information. Tests for
association and linear trend for both SIR and AER were based on
Poisson regression models (Breslow and Day, 1987; Boshuizen and
Feskens, 2010). Cumulative CTGCT incidence and confidence
intervals were estimated in the presence of death as competing risk
(Gooley et al, 1999; Choudhury 2002).
Effects of TGCT treatment on metachronous CTGCT risk were
quantified using multivariable regression with death as competing
risk (Fine and Gray, 1999). To compare the risk of subsequent
non-TGCT cancer with and without a prior CTGCT we used a
competing risk regression model (death as competing risk) with
CTGCT as a time-dependent covariate, allocating follow-up time to
the ‘no CTGCT’ group until metachronous CTGCT occurrence.
The model also included age at primary TGCT diagnosis and
receipt of radiotherapy and chemotherapy for the primary TGCT
(or for any recurrence of this cancer before the CTGCT diagnosis).
Similarly, we used a Cox model with CTGCT as a time-dependent
covariate, to compare survival with and without a CTGCT. This
model used attained age as time-scale and also adjusted for age at
diagnosis and histology of the primary TGCT, period of treatment
and receipt of radiotherapy and chemotherapy for the primary
TGCT (or radiotherapy or chemotherapy for any recurrence of this
cancer before the CTGCT diagnosis). Three patients with a CTGCT
had an invasive non-testis cancer (two stomach cancers and one
lung cancer) before the development of their CTGCT, whereas
another 396 had an invasive non-testis cancer other than non-
melanoma skin cancer but no CTGCT. The three patients with a
second cancer before their CTGCT were not censored in the
analysis of CTGCT risk factors, but were censored in the analysis
of survival after a CTGCT and in the analysis of the impact of
developing a CTGCT on the risk of an invasive non-testis cancer
and the risk of death after a primary TGCT, where the CTGCT was
treated as a time-dependent event.
Analyses were performed using STATA statistical software (Stata
11, StataCorp. LP, College Station, TX, USA) and a P-value o0.05
was considered statistically significant.
RESULTS
The cohort comprised 1716 (45.8%) seminoma and 2033 (54.2%)
non-seminoma TGCT patients (Table 1). The majority of
seminoma patients (86.9%) received radiotherapy, whereas most
non-seminoma patients either received chemotherapy (61.8%) or
surgery alone (24.4%). The median follow-up was 18.5 years; 23.7%
of the survivors accumulated X25 follow-up years.
Eighty-seven patients, 48 with a primary seminoma and 39 with a
non-seminoma TGCT, developed a CTGCT. Ten CTGCTs were
diagnosed within 6 months of the primary TGCT (synchronous CTGCT),
nine among seminoma (seven of which were also of the seminoma
subtype) and one (a seminoma) among non-seminoma patients.
The remaining 77 CTGCTs were diagnosedX6 months after the
primary TGCT. The median interval until diagnosis of these
metachronous CTGCT did not differ between seminoma and non-
seminoma patients (8.5 years, range 0.8–23.9 years) and 63.6%
occurred within 10 years of the primary TGCT. Only two
metachronous CTGCT were diagnosed after 420 year. Three
metachronous CTGCT patients also experienced a relapse, which
preceded the CTGCT in all cases. Irrespective of TGCT histology,
metachronous CTGCTs were more frequently of the seminoma
than of the non-seminoma subtype; 32 (82%) CTGCTs among
seminoma and 23 (61%) CTGCTs among non-seminoma patients
were seminomas.
Relative risk compared with the general population
Overall, the incidence of metachronous CTGCT in our cohort was
17.6 (95% CI 13.9–22.0) times higher than the expected TGCT
incidence based on general population rates (Table 2). The SIRs
did not vary by age at TGCT diagnosis (Pheterogeneity¼ 0.19) or
follow-up duration (Ptrend¼ 0.13, restricted to the first 25 years of
follow-up). The SIR was lower for patients diagnosed in the period
1976–1985 and 1986–1995 compared with patients diagnosed
during 1965–1975 (1976–1985 vs 1965–1975: relative risk (RR) 0.38,
P¼ 0.001; 1986–1995 vs 1965–1975: RR 0.32, Po0.001).
The SIR was 24.9 after a seminoma and 13.6 after a non-
seminoma TGCT (seminoma vs non-seminoma: RR 1.84,
P¼ 0.008). The SIR was significantly lower for non-seminoma
patients treated with chemotherapy (SIR 7.6, 95% CI 4.3–12.6)
compared with patients treated without chemotherapy
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(chemotherapy vs no chemotherapy: RR 0.30, Po0.001). This
association remained after adjusting for period of diagnosis and
follow-up interval (chemotherapy vs no chemotherapy: RR 0.34,
Po0.001, data not shown). For non-seminoma patients who
received chemotherapy the median time until metachronous
CTGCT was 9.1 years compared with 8.2 years for those treated
without chemotherapy (P¼ 0.45).
Absolute excess risk compared with the general population
We observed 11.4 excess CTGCTs (95% CI 8.9–14.4) for every 1000
patients followed for 10 years (Table 2). The AER decreased with age
for seminoma (Ptrend¼ 0.015) and, nonsignificantly, for non-
seminoma patients (Ptrend¼ 0.067), but the number of events in
the age category X40 years was very small among the non-
seminoma patients. The AER did not vary by treatment period for
either seminoma or non-seminoma. The AER did vary with primary
treatment among non-seminoma patients (Pheterogeneityo0.001), with
a lower AER for patients treated with chemotherapy (AER 5.8, 95%
CI 2.9–10.2) compared with patients treated without chemotherapy
(AER chemotherapy vs no chemotherapy: P¼ 0.001).
Cumulative incidence
The cumulative incidence of metachronous CTGCT was 1.4% (95%
CI 1.0–1.8%) after 10 years and 2.2% (95% CI 1.8–2.8%) after 20
years of follow-up (Table 2). Cumulative incidence increased at a
fairly constant rate during the follow-up and reached a plateau
after 20 years of follow-up; no CTGCT was diagnosed after the 24th
year of follow-up.
Among seminoma patients, only age at diagnosis was found to
be associated with CTGCT cumulative incidence. At 20 years of
follow-up, seminoma patients o30 years had a cumulative
incidence of 4.3% (95% CI 2.4–7.0%), but incidence decreased
for patients who were older at TGCT diagnosis (hazard ratio (HR)
per 10-year increase: 0.47, 95% CI 0.26–0.84, data not shown).
Figure 1 shows the cumulative incidence by attained age according
to age at diagnosis (o30 years vs X30 years) for seminoma
patients. The CTGCT incidence increased much more rapid by
attained age for younger patients (HR 0.30 for X30 years vs o30
years, Po0.001).
Chemotherapy for non-seminoma TGCT was associated with a
significantly lower cumulative CTGCT incidence (Figure 2).
However, although receipt of chemotherapy was associated with
a43-fold reduction in cumulative CTGCT incidence (HR 0.28 for
chemotherapy vs no chemotherapy, Po0.001) among patients
o30 years, the reduction appeared slightly more limited for
patients X30 years at diagnosis (chemotherapy vs no chemother-
apy: HR 0.42, P¼ 0.16). In multivariable analysis, period of
diagnosis did not affect CTGCT risk, whereas older age at
diagnosis was associated with a slightly lower CTGCT risk.
Platinum-based chemotherapy was associated with a lower CTGCT
risk among non-seminoma patients (HR 0.37, 95% CI 0.19–0.77;
Table 3). Although only based on two CTGCT, non-platinum
regimens appeared also associated with lower CTGCT risk.
Association of metachronous CTGCT with survival
The 5- and 10-year overall survival rates after metachronous
CTGCT diagnosis for the 74 patients without a prior non-testis
second cancer were 93.0% (95% CI 84.3–97.1) and 86.1% (95% CI
74.7–92.6), respectively. Median age at time of death for deceased
patients was 49.7 years (range 33–67 years). Only 2 of these 74
CTGCT patients died directly due to disseminated testicular
cancer, whereas 9 other CTGCT patients died due to a non-testis
second cancer (Supplementary Table S1). Thirteen of these CTGCT
patients (22.1%) had at least one other non-TGCT secondary
cancer after their primary TGCT. Patients with a metachronous
CTGCT had a 2.3 times (95% CI 1.3–4.1, P¼ 0.006) higher risk of
developing a subsequent non-TGCT invasive cancer (adjusted for
age, chemotherapy and radiotherapy for primary TGCT; data not
shown). On the basis of 16 deaths among the 74 CTGCT patients
without a prior non-testis second cancer, patients with a CTGCT
also had a 1.8 times higher risk (95% CI 1.1–2.9, P¼ 0.026; data not
shown) of death than patients who did not develop a CTGCT.
DISCUSSION
In this large cohort study TGCT patients had an almost 18-fold
increased risk to develop a metachronous CTGCT compared with
the Dutch male population. When considering that TGCT-
survivors have only one testicle at risk for CTGCTs, while the
reference rates for the general population concern cancer in any of
two testes, the risk expressed in testis-years could even be twice as
high. The 20-year cumulative CTGCT incidence reached 2.2%,
indicating that conditional on surviving, about one in every 45
TGCT patients will develop a CTGCT within 20 years of their
primary TGCT. Non-seminoma TGCT treatment with platinum-
based chemotherapy was associated with a lower CTGCT risk. A
CTGCT diagnosis was associated with worse prognosis, mostly due
to deaths from subsequent non-TGCT malignancies.
This study is to our knowledge the largest cohort study on
CTGCT risk with complete treatment data and complete follow-up
Table 1 Patient characteristics
Seminoma Non-seminoma
Number % Number %
All patients 1716 100.0 2033 100.0
Age
Median age (IQR) 38.2 (31.7–46.8) 28.2 (23.3–34.6)
o30 336 19.6 1176 57.9
30–39 636 37.1 571 28.1
40–49 424 24.7 190 9.4
X50 320 18.7 96 4.7
Treatment period
1965–1975 401 23.4 374 18.4
1976–1985 635 37.0 835 41.1
1986–1995 680 39.6 824 40.5
Stage
Stage I 982 57.2 749 36.8
Stage II 341 19.9 520 25.6
Stage III/IV 87 5.1 473 23.3
Stage unknown 306 17.8 291 14.3
Total treatmenta
Surgery±RT 1413 82.3 775 38.1
Platinum-based CT 222 12.9 970 47.7
Other CT 81 4.7 288 14.2
Recurrence
No 1598 93.1 1831 90.1
Yes 118 6.9 202 9.9
Vital status
Alive 1123 68.2 1419 71.3
Dead 552 32.2 570 28.1
Lost to follow-up 41 2.4 44 2.2
Abbreviations: CT¼ chemotherapy; IQR¼ inter quartile range; RT¼ radiotherapy.
aAll treatment administered after surgery (orchiectomy with or without retro-
peritoneal lymph node dissection), including treatment for relapse/recurrence before
metachronous CTGCT diagnosis.
Risk of contralateral testicular cancer
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for CTGCT. Our analysis of CTGCT risk was based on all treatment
received before CTGCT diagnosis, which allows reliable assessment
of the effect of treatment on CTGCT risk. In studies based on data
from population-based cancer registries, treatment misclassifica-
tion is a common problem, either due to underreporting of
chemotherapy in initial treatment or due to omission of salvage
Table 2 Number of patients (N), observed number (O), SIR, AER per 10 000 person-years and 10-, and 20-year cumulative incidence (%) for





























Seminoma and non-seminoma combined
All patients 3608 63 635 77 17.6 (13.9–22.0) 11.4 (8.9–14.4) 2963 49 1.4 (1.0–1.8) 1554 75 2.2 (1.8–2.8)
Age
o30 1451 25 633 40 14.9 (10.6–20.3) 14.6 (10.1–20.2) 1198 23 1.6 (1.1–2.4) 640 40 3.0 (2.2–4.1)
30–39 1180 21 716 26 20.8 (13.6–30.5) 11.4 (7.2–17.0) 995 20 1.7 (1.1–2.6) 536 24 2.2 (1.4–3.2)
X40 977 16 286 11 25.3 (12.6–45.3) 6.5 (3.1–11.8) 770 6 0.6 (0.3–1.3) 378 11 1.2 (0.6–2.0)
Treatment period
1965–1975 725 14 633 22 41.1 (25.8–62.3) 14.7 (9.0–22.4) 490 14 1.9 (1.1–3.2) 409 21 2.9 (1.9–4.3)
1976–1985 1403 28 168 27 15.8 (10.4–23.0) 9.0 (5.7–13.3) 1184 13 0.9 (0.5–1.6) 985 26 1.9 (1.3–2.7)
1986–1995 1480 20 834 28 13.2 (8.7–19.0) 12.4 (7.9–18.4) 1289 22 1.5 (1.0–2.2) 160 28 2.0 (1.4–2.9)
Total treatmentb
Surgeryc 2127 41 274 62 25.8 (19.7–33.0) 14.4 (10.9–18.7) 1859 40 1.9 (1.4–2.6) 1055 60 3.0 (2.3–3.9)
Platinum-based CTc 1149 18 182 13 7.5 (4.0–12.9) 6.2 (2.9–11.3) 950 8 0.7 (0.3–1.3) 372 13 1.2 (0.7–1.2)
Other CTc 332 4179 2 8.5 (1.0–30.7) 4.2 (0.2–16.7) 154 1 0.3 (0.0–1.6) 127 2 0.6 (0.1–2.1)
Follow-up interval (years)d,e
0.5–4 3608 14 817 24 21.2 (13.6–31.5) 15.4 (9.6–23.3)
5–9 3136 15 338 25 19.7 (12.8–29.1) 15.5 (9.7–23.2)
10–14 2963 13 416 17 16.7 (9.7–26.7) 11.9 (6.6–19.5)
15–19 2313 9747 9 15.7 (7.2–29.8) 8.6 (3.6–16.9)
20–24 1554 5888 2 7.8 (0.9–28.2) 3.0 ( 0.2 to 11.8)
Seminoma
All patients 1675 30 531 39 24.9 (17.7–34.0) 12.3 (8.6–17.0) 1413 25 1.5 (1.0–2.2) 744 37 2.4 (1.7–3.2)
Age
o30 323 6060 13 22.5 (12.0–38.5) 20.5 (10.5–35.7) 280 8 2.5 (1.2–4.7) 156 13 4.3 (2.4–7.0)
30–39 630 12 074 17 25.7 (15.0–41.1) 13.5 (7.7–22.0) 554 12 1.9 (1.1–3.3) 294 15 2.6 (1.5–4.2)
X40 722 12 397 9 27.4 (12.5–52.0) 7.0 (3.1–13.5) 579 5 0.7 (0.3–1.6) 294 9 1.3 (0.6–2.4)
Treatment period
1965–1975 393 8880 14 48.6 (26.6–81.6) 15.4 (8.3–26.1) 306 7 1.8 (0.8–3.5) 252 13 3.3 (1.9–5.4)
1976–1985 613 12 381 11 20.3 (10.1–36.2) 8.4 (4.0–15.5) 534 7 1.2 (0.5–2.3) 416 10 1.7 (0.9–3.0)
1986–1995 669 9270 14 19.9 (10.4–31.9) 14.3 (7.5–24.5) 573 11 1.7 (0.9–2.9) 76 14 2.3 (1.3–3.7)
Total treatmentb
Surgeryc 1387 26 654 37 27.8 (19.6–38.6) 13.4 (9.3–18.6) 1213 24 1.8 (1.2–2.6) 673 35 2.7 (1.9–3.7)
Platinum-based CTc,f 209 3148 1 4.9 (0.1–27.5) 2.5 ( 0.6 to 17.1) 172 0 0.0 51 1 0.5 (0.0–2.6)
Other CTc 79 729 1 29.8 (0.8–165.8) 13.2 ( 0.1 to 75.9) 28 1 1.3 (0.1–6.1) 20 1 1.3 (0.1–6.1)
Follow-up interval (years)d,e
0.5–4 1675 7123 13 27.9 (14.8–47.7) 17.6 (9.1–30.6)
5–9 1515 7388 12 25.9 (13.4–45.3) 15.6 (7.8–27.7)
10–14 1413 6342 9 27.0 (12.3–51.2) 13.7 (6.0–26.4)
15–19 1080 4585 3 16.9 (3.5–49.4) 6.2 (1.0–18.7)
20–24 744 2789 2 24.6 (3.0–89.0) 6.9 (0.6–25.6)
Non-seminoma
All patients 1933 33 104 38 13.6 (9.6–18.6) 10.6 (7.3–14.9) 1550 24 1.3 (0.8–1.8) 810 38 2.2 (1.5–2.9)
Age
o30 1128 19 573 27 12.8 (8.6–19.1) 12.7 (8.0–19.0) 918 15 1.3 (0.8–2.2) 484 27 2.7 (1.8–3.9)
30–39 550 9641 9 15.3 (7.0–29.5) 8.7 (3.7–17.1) 441 8 1.5 (0.7–2.8) 242 9 1.7 (0.8–3.0)
X40 255 3890 2 18.9 (2.3–68.2) 4.9 (0.4–18.3) 191 1 0.4 (0.0–2.0) 84 2 0.8 (0.2–2.6)
Treatment period
1965–1975 332 5573 8 32.4 (14.0–63.8) 13.5 (5.6–27.0) 184 7 2.1 (0.9–4.1) 157 8 2.4 (1.1–4.5)
1976–1985 790 15 787 16 13.7 (7.8–22.3) 9.4 (5.1–15.7) 650 6 0.8 (0.3–1.6) 569 16 2.1 (1.2–3.3)
1986–1995 811 11 564 14 10.1 (5.5–16.9) 10.9 (5.4–19.1) 716 11 1.4 (0.7–2.4) 84 14 1.8 (1.1–3.0)
Total treatmentb
Surgeryc 740 14 620 25 23.2 (15.0–34.3) 16.4 (10.3–24.5) 646 16 2.2 (1.3–3.5) 382 25 3.7 (2.4–5.3)
Platinum-based CTc,f 940 15 034 12 7.9 (4.1–13.7) 7.0 (3.1–12.9) 778 8 0.9 (0.4–1.6) 321 12 1.4 (0.7–2.3)
Other CTc 253 3450 1 5.0 (0.1–27.6) 2.3 ( 0.5 to 15.6) 126 0 0.0 107 1 0.4 (0.0–2.1)
Follow-up interval (years)d,e
0.5–4 1993 7694 11 16.5 (8.2–29.5) 13.4 (6.3–24.7)
5–9 1621 7950 13 16.2 (8.6–27.6) 15.3 (7.7–27.0)
10–14 1550 7075 8 11.7 (5.0–23.0) 10.3 (3.9–21.3)
15–19 1233 5162 6 15.2 (5.6–33.0) 10.9 (3.5–11.3)
20–24 810 3099 0 0.0 (0.0–21.1)  0.4 ( 0.4 to 24.7)
Abbreviations: AER¼ absolute excess risk; 95% CI¼ 95% confidence interval; CTGCT¼ contralateral testicular germ cell tumour; CT¼ chemotherapy; SIR¼ standardised
incidence ratio; TGCT¼ testicular germ cell tumour. aIncludes three patients, two seminoma and one non-seminoma, with a non-testis second cancer (two stomach cancers,
treated with surgery only, and one lung cancer) before the CTGCT diagnosis. bIncludes treatment for relapse/recurrence before metachronous CTGCT diagnosis. cWith or
without radiotherapy. dNumber at risk at begin of interval. ePerson-time in follow-up interval X25 years: 2305 for seminoma and 2123 years for non-seminoma (4428 for
combined group). fTwo patients with 2xBEP (Bleomycin, Etoposide, Cisplatin), one patient with 3xBEPþ 1xEP (Etoposide, Cisplatin), four patients with 4xBEP, one patient with
4xEP, one patient with 4xCEB (Carboplatin, Etoposide, Bleomycin), one patient with 4xVIP (Etoposide, Ifosfamide, Cisplatin), three patients with 4xPVB (Cisplatin, Vinblastin,
Bleomycin).
Risk of contralateral testicular cancer
M Schaapveld et al
1640










treatment, thus limiting conclusions regarding the association of
TGCT treatment with CTGCT risk (Osterlind et al, 1991; Fossa˚
et al, 2005; Andreassen et al, 2011).
Testicular intraepithelial neoplasms (TINs) are considered
precursor lesions for seminoma and non-seminoma TGCT. In a
Danish study, contralateral testicle biopsies of 500 TGCT patients
revealed contralateral TIN lesions in 5.4% (von der Maase et al,
1986). Fifty percent of the patients with a TIN lesion, who did not
receive chemotherapy, developed an invasive TGCT within 5 years,
whereas none of the patients who received platinum-based
chemotherapy did so, suggesting that platinum-based chemother-
apy eradicated TIN lesions. Nonetheless, Greist et al (1984) found
residual carcinoma in the removed testes of 3 out of 20 patients
who underwent orchiectomy after platinum-based chemotherapy
for disseminated TGCT. Recently, Kleinschmidt et al (2009)
reported persistent TIN after rebiopsy among 5 out of 11 patients
with a primary TIN who had received platinum-based chemother-
apy, 2 of whom later developed an invasive TGCT. The Danish
group also showed that among 33 patients with disseminated
TGCT and a contralateral TIN lesion, all treated with chemother-
apy (BEP 26, PVB 6, other 1), 4 patients still developed a CTGCT
(Christensen et al, 1998). Other studies also reported CTGCT
among patients treated with cisplatinum-containing chemotherapy
(Wandera˚s et al, 1997; Theodore et al, 2004; Hentrich et al, 2005;
van den Belt-Dusebout et al, 2007). In our study, 12 of the 77
metachronous CTGCT were diagnosed in non-seminoma patients
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<30 vs30: HR 0.30, P<0.001
Age<30
Age30
Figure 1 Cumulative incidence with 95% CIs of metachronous CTGCTs
for patients with a seminoma TGCT by attained age, according to age at
diagnosis (o30 vs X30 years).
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CT vs no CT: HR 0.28, P =0.002
Non-seminoma TGCT, age at dx <30 years
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9.0 CT vs no CT: HR 0.42, P =0.163
Non-seminoma TGCT, age at dx 30 years
Figure 2 Cumulative incidence with 95% CIs of CTGCTs for patients
with a non-seminoma TGCT by attained age, according to treatment with
and without chemotherapy and age at diagnosis (A: o30 years; B: X30
years).
Table 3 Multivariate regression analysis of risk factors for the occurrence of metachronous CTGCTs during follow-up (death as competing risk)
Non-seminoma TGCT only All TGCTs
Model 1 Model 2
Risk factor HR 95% CI P-value HR 95% CI P-value HR 95% CI P-value
Agea 0.75 0.55–1.00 0.049 0.74 0.55–1.00 0.053 0.67 0.54–0.83 o0.001
Histology — 0.683
Seminoma — — — — — 1.00 Ref
Non-seminoma — — — — — 0.89 0.52–1.52
Chemotherapyb 0.001 — —
No 1.00 Ref — — — —
Yes 0.31 0.16–0.60 — — — —
Chemotherapyb — 0.003 o0.001
None — — 1.00 Ref 1.00 Ref
Platinum-based CT — — 0.37 0.18–0.72 0.34 0.18–0.63
Other CT — — 0.11 0.01–0.78 0.17 0.04–0.72
Abbreviations: 95% CI¼ 95% confidence interval; CTGCT¼ contralateral testicular germ cell tumour; CT¼ chemotherapy; HR¼ (subdistribution) hazard ratio; TGCT¼
testicular germ cell tumour. Model 1: chemotherapy (CT) entered in the model as yes vs no. Model 2: chemotherapy (CT) entered in the model as platinum-based CT or other
CT (vs none). aAge, centred to the mean, continuous, every 10-year increase. bIncludes treatment for relapse/recurrence before metachronous CTGCT diagnosis.
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treated with platinum-based chemotherapy (PVB 3 patients, BEP 7
patients, EP 1 patient, VIP 1 patient, CEB 1 patient). Therefore, it
appears that platinum-based chemotherapy does not completely
block the development of CTGCT.
Our study does not lend support to delayed CTGCT develop-
ment after platinum-based chemotherapy, as postulated by
Christensen et al (1998). With a median follow-up of 18.5 years
we found no difference in the distribution of CTGCT by follow-up
time between non-seminoma patients treated with or without
chemotherapy (9.1 vs 8.2 years). The occurrence of metachronous
CTGCTs after 410 years of follow-up (36% of CTGCTs in our
cohort) proved to be no rare event. Similarly, a study among
Norwegian males treated at the Radium Hospital reported that
17% of all CTGCTs were diagnosed after X10 years, whereas in a
US study 30% of all CTGCTs were diagnosed after X10 years of
follow-up (Wandera˚s et al, 1997; Che et al, 2002). Assuming that all
CTGCTs derive from a pre-existing TIN, that the prevalence of TIN
is 5% (based on biopsy studies) and that our estimate of the 10-
year cumulative incidence (2.2%) is correct, we would expect that
the risk of progression to invasive cancer within 5 years would be
o50% currently reported (von der Maase et al, 1986; Dieckmann
et al, 2007).
Incidence patterns for metachronous CTGCTs by age group
appear to mimic incidence patterns of de novo TGCTs. Although
the SIR for CTGCT did not differ by age at TGCT diagnosis, the
cumulative incidence decreased with older age at TGCT diagnosis.
Although a decreasing CTGCT risk with older age at primary
TGCT diagnosis has been observed in several other studies
(Wandera˚s et al, 1997; Theodore et al, 2004; Fossa˚ et al, 2005),
no good explanation for this finding has been given. One could
speculate that patients who develop testicular cancer later in life
are less likely to harbour premalignant cells in the contralateral
testis or that a lower fraction of contralateral TIN lesions
transforms into invasive tumour among older patients.
The occurrence of a CTGCT appeared to affect patient’s
prognosis in our cohort. This may partly reflect the impact of
additional CTGCT treatment on late treatment complications,
especially non-testis second cancers, as suggested by the two-fold
risk increase for a non-testis second cancer among patients with a
CTGCT compared with patients without a CTGCT in our study.
In contrast with our results, Fossa˚ et al (2005) previously found
no indication that prognosis for a TGCT patient was compromised
by the diagnosis of a metachronous CTGCT and even found a
slightly lower risk of death for patients with a CTGCT (HR 0.76;
95% CI 0.45–1.26). The cohort studied by Fossa˚ et al was
diagnosed in a more recent time period; 86% of all included
patients in their study were diagnosed with a primary TGCT since
1983. In our cohort 49% of all patients were diagnosed before 1983,
in a period in which higher radiation doses and more extensive
radiation fields were used.
A potential weakness of our study is that we did not collect
information on a history of testicular maldescent, testicular
trauma, infertility, testicular atrophy or removal of a testis due
to trauma or maldescent. Although these factors could be
associated with the risk of developing a CTGCT, they are unlikely
to be associated with treatment for the primary testicular cancer
and will therefore not confound the reduced risk estimate of
CTGCT, which we observed among patients treated with
(platinum-based) chemotherapy.
Clinicians can use the results of our study to inform and
reassure patients under long-term follow-up about their very low
remaining risk to develop a CTGCT. In addition, patients treated
with chemotherapy can be informed that albeit they have a very
low risk to develop a CTGCT, the risk is not absent. On the basis of
our results clinicians should be aware that especially young
seminoma patients and young non-seminoma patients, not treated
with chemotherapy, have a relatively high risk to develop a
CTGCT, reaching about 4%, 20 years after the primary TGCT.
Conclusions
Treatment of non-seminoma TGCT with platinum-based che-
motherapy is associated with a markedly lower CTGCT risk. The
CTGCT risk remains elevated for at least 20 years, at which time
the cumulative incidence reaches 2.2%.
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